



Regulatory Circular RG01-97

DATE: June 28, 2001
TO: Members and Member Firms
FROM: Market Operations Department
RE: Restrictions on Transactions in
Cytogen Corporation

Trading in specific series in [Cytogen Corporation \(CYTO/UOR\)](#) has been restricted. The UOR Feb 5, 7½ and 10 options series have been restricted to closing customer orders only.

Only closing transactions may be effected in the UOR Feb 5, 7½ and 10 options series, except for (i) opening transactions by market-makers executed to accommodate closing transactions of other market participants and (ii) opening transactions by CBOE member organizations to facilitate the closing transactions of public customers executed as crosses pursuant to and in accordance with CBOE Rule 6.74(b or d). The UOR Feb 5, 7½ and 10 options series will not be traded on RAES.

The execution of opening transactions in the UOR Feb 5, 7½ and 10 options series, except as permitted above, and/or the misrepresentation as to whether an order is opening or closing, will constitute a violation of CBOE rules, and may result in disciplinary action.

There are no restrictions in place with respect to the exercise of UOR options and the Options Clearing Corporation (OCC) has advised CBOE that the expiration of UOR options will remain subject to OCC's Exercise-by-Exception Procedures.

Any questions regarding this circular may directed to Kerry Winters at (312) 786-7312.